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Introduction: Enzastaurin is an oral serine/threonine kinase inhib-
itor, which suppress signaling through protein kinase C- and the
phosphatidylinositol 3-kinase/AKT pathway. Preclinical studies
suggested synergic antitumor activity of enzastaurin and pem-
etrexed. We conducted this phase I study to evaluate the safety,
pharmacokinetics, and clinical activity of this combination in pa-
tients with previously treated advanced non-small cell lung cancer.
Methods: An oral daily dose of 500 mg enzastaurin was adminis-
tered once daily (QD) or twice daily (BID) in combination with 500
mg/m2 pemetrexed on day 1 in repeated 21-day cycles. Cycle 1
started with a 7-day enzastaurin lead-in treatment that preceded
pemetrexed administration: a loading dose of 1125 mg enzastaurin
on day 1 followed by a 500 mg total daily dose on days 2–7.
Results: Twelve patients were treated QD (n  6) or BID (n  6).
One dose-limiting toxicity (grade 3 QTc prolongation) was reported
in the QD cohort. Grade 3/4 hematological toxicities were slightly
increased in the BID cohort compared with the QD cohort. After
beginning the combination therapy, enzastaurin exposures decreased
slightly but remained above the target plasma concentration of 1400
nmol/L. Compared with QD, there was a higher exposure with BID.
The enzastaurin dosing regimen (QD or BID) had no effect on
pemetrexed pharmacokinetics. Two patients had partial responses as
defined by RECIST. Five patients received more than 10 cycles of
treatment without disease progression.
Conclusions: Both schedules of enzastaurin in combination with
pemetrexed were well tolerated and clinically active in patients with
advanced non-small cell lung cancer.
Key Words: Enzastaurin, Pemetrexed, Non-small cell lung cancer,
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Lung cancer remains the leading cause of cancer mortalityin the world. Platinum-based combination chemotherapy
offers a survival benefit in patients with chemo-naïve advanced
non-small cell lung cancer (NSCLC).1,2 Nevertheless, the effi-
cacy of platinum-based combination chemotherapy seems to
have reached a therapeutic plateau, with a median survival of 8
to 12 months.3,4 Several agents have been approved for second-
and third-line therapy, including docetaxel,5,6 pemetrexed7, and
erlotinib.8 Nevertheless, they improve survival by only approx-
imately 2.2 to 6.5 months compared with best supportive
care.5–8 A more effective therapy is needed.
Pemetrexed, a multitargeted antifolate, is currently ap-
proved as a first- and second-line therapy for locally advanced or
metastatic NSCLC. The standard regimen of pemetrexed is 500
mg/m2, administered intravenously (IV) on day 1 in repeated
21-day cycles, supplemented with folic acid and vitamin B12.
Enzastaurin (LY317615), an oral serine/threonine ki-
nase inhibitor, suppress signaling through protein kinase C
(PKC)- and the phosphatidylinositol 3-kinase/AKT path-
way.9–12 Enzastaurin is metabolized primarily by cytochrome
P450 3A (CYP3A) to form a desmethylenepyrimidyl metab-
olite (LY326020) and a desmethyl metabolite (LY485912), two
active metabolites with comparable potency against PKC. In
vitro analysis has shown that the IC90 of enzastaurin for PKC
is 70 nmol/L.9 In light of the 95% plasma protein binding value
of enzastaurin, the targeted mean steady state total concentration
for clinical efficacy is estimated to be 1400 nmol/L. In a
previous dose-escalation study (20–700 mg once daily [QD]) of
patients with cancer, enzastaurin exposures reached a plateau
above the targeted steady-state plasma concentration of
1400 nmol/L when administered at doses of 525 mg.13 This
dose was well tolerated, and enzastaurin at 500 mg QD
demonstrated clinical activity as a single agent and in
combination with cytotoxic agents.14 –17
The combination of enzastaurin and pemetrexed has
shown synergic antitumor activity in NSCLC cells.18–20 Pre-
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clinical studies revealed that enzastaurin suppressed thymi-
dylate synthase (TS) expression through downregulation of
E2F.21 TS expression is one of the known sensitivity markers
for pemetrexed, with pemetrexed treatment markedly increas-
ing transcription of the TS gene. However, the combination of
enzastaurin and pemetrexed significantly decrease TS activity
and reduced glycogen synthase kinase-3beta/AKT phosphor-
ylation and vascular endothelial growth factor secretion.21
Therefore, evidence points to enzastaurin as a promising
agent to increase the activity of pemetrexed.
In vitro analysis showed that twice daily (BID) dosing
could maintain enzastaurin exposures above the targeted
plasma concentration longer than QD dosing (data at Eli Lilly
on file), which was confirmed in phase I studies.15,17 We
conducted this study to assess safety and tolerability of two
dosing regimens of total daily 500 mg enzastaurin (QD or
BID) in combination of pemetrexed.
The primary objective was to evaluate the safety of the
combination of enzastaurin and pemetrexed in Japanese ad-
vanced NSCLC patients with prior systemic chemotherapy. The
secondary objectives were to evaluate the toxicities of this
combination and determine the pharmacokinetics of enzastaurin
with or without pemetrexed. Antitumor activity of this combi-
nation was also assessed. We started with enzastaurin 500 mg
QD in combination with pemetrexed to confirm safety in the QD
cohorts. After this, we proceeded to 250 mg BID.
PATIENTS AND METHODS
Patients
Eligibility criteria included the following: histologi-
cally or cytologically documented NSCLC; clinical stage IV
or IIIB (including only patients with no indications for
curative radiotherapy) or relapse after surgery; one or two
prior systemic chemotherapy regimens, including at least one
platinum-based regimen for NSCLC; presence of at least one
measurable disease as defined by the Response Evaluation
Criteria in Solid Tumors (RECIST); 20 to 75 years of age;
Eastern Cooperative Oncology Group performance status of 0
to 2; adequate bone marrow reserve, hepatic, renal, and pulmo-
nary function; predicted life expectancy of at least 12 weeks;
recovery from toxicities of all previous therapies for NSCLC
(had not received radiotherapy 28 days, chemotherapy 28
days, nitrosourea 42 days, hormone therapy 14 days, mo-
lecular targeted therapy14 days, Uracil-Tegafur14 days, or
doxifluridine 14 days before enrollment).
Exclusion criteria were the following: interstitial pneumo-
nia or pulmonary fibrosis detectable on radiologic evaluation;
history of tube thoracostomy drainage for pleural effusion;
inability to swallow capsules; myocardial infarction that oc-
curred less than 6 months before entry; symptomatic angina
pectoris, cardiac failure, arrhythmia not controlled by medica-
tion; prolonged QTc interval 450 milliseconds; symptomatic
central nervous system metastasis; chronic use of nonsteroidal
anti-inflammatory drugs; pregnancy; and serious comorbidity.
The study was approved by the institutional review
boards of each participating institution and was conducted in
accordance with the Declaration of Helsinki and good clinical
practice and in compliance with all applicable laws and
regulations. Written informed consent was given by each
patient before study enrollment.
Study Design and Treatment Plan
This was an open-label, nonrandomized, multicenter
study designed to assess safety and pharmacokinetics of enza-
staurin administered QD (cohort 1) or BID (cohort 2) in com-
bination with the standard dose of pemetrexed. During stage 1 of
cycle 1, patients received a loading dose of enzastaurin (375 mg,
3 times, 1125 mg total dose) on day 1 followed by 500 mg total
daily dose on days 2 through 7 of cycle 1 (Figure 1) to achieve
the targeted steady-state concentration (1400 nmol/L).9,13 Dur-
ing stage 2 of cycle 1, an oral daily dose of 500 mg enzastaurin
was administered within half an hour after meals QD or BID.
This was continued in cycle 2 and thereafter. Patients received
standard pemetrexed as a 10-minute IV dose of 500 mg/m2 on
day 1 of stage 2 of cycle 1 and subsequently in a repeated 21-day
cycle. On days of pemetrexed dosing, enzastaurin was admin-
istered after pemetrexed. We started with 500 mg QD (cohort 1),
and after confirming safety, serially enrolled the BID cohorts
and proceeded with 250 mg BID (cohort 2).
FIGURE 1. Study design and phar-
macokinetic plan. An oral daily dose of
500 mg enzastaurin was given once
daily (QD) in cohort 1 or twice daily
(BID) in cohort 2 in combination with
500 mg/m2 pemetrexed on day 1 in
repeated 21-day cycles. Cycle 1 started
with a 7-day enzastaurin lead-in treat-
ment that preceded pemetrexed ad-
ministration: a loading dose of 1125
mg enzastaurin on day 1 followed by
500 mg total daily dose on days 2–7.
Pharmacokinetic (PK) sampling is indi-
cated by chevrons. All patients received
standard daily folate and vitamin
B12 supplementation per standard
treatment guidelines for pemetrexed
infusion.
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Each cohort was initially designed to enroll six patients.
If three or more patients in each cohort experienced dose-
limiting toxicities (DLTs) during cycle 1, the recruitment was
to be ended. A DLT was defined as any of the following
drug-related adverse events during cycle 1: (1) hematological
toxicity, as determined by the Common Terminology Criteria
for Adverse Events version 3.0: grade 4 neutropenia that
persisted for 7 days or more, febrile neutropenia, grade 4
thrombocytopenia, or grade 3 thrombocytopenia with hem-
orrhage or requiring a blood transfusion; (2) grade 3/4 non-
hematologic toxicities except for the following manageable
events: nausea, vomiting, loss of appetite, fatigue, constipa-
tion, diarrhea, transient aspartate aminotransferase or alanine
transaminase elevation, and transient electrolyte abnormality;
(3) grade 3 corrected QT (QTc) prolongation 500 millisec-
onds or an increase 60 milliseconds over baseline QT
measured at entry.
Safety Assessments
Physical examination results, vital signs (blood pres-
sure, pulse rate, and body temperature), and performance
status were evaluated at baseline, on day 1, and weekly
during treatment. Complete blood count, serum chemistry,
and urinalysis were performed at baseline and weekly during
treatment. Twelve-lead electrocardiograms were recorded at
baseline, 4–6 hours after the first dosing of enzastaurin on
days 1 to 3 during stage 1, and at one point determined by the
investigator between days 1 and 8 of each cycle. QTc values
were obtained using Bazett’s method of correction.22
Pharmacokinetic Measurements and Analyses
In cohort 1, blood samples for enzastaurin pharmaco-
kinetics were collected on the following days (Figure 1): day
1 (before dosing and 4 hours after dosing), day 2 (before
dosing and 2, 4, 6, 8, and 24 hours after dosing), and day 8
(before dosing) of cycle 1, and day 1 (before dosing and 2, 4,
6, 8, and 24 hours after dosing) of cycle 2. In cohort 2, blood
samples were collected at the same points as cohort 1 except
that the 24-hour collection time points after the first dose in
cycles 1 and 2 was changed to 12 hours. Blood samples for
pemetrexed pharmacokinetics were collected on day 1 (10
minutes, 2, 4, 6, 8, and 24 hours after dosing) and day 3
(before dosing) of cycle 2.
Pemetrexed plasma concentrations were measured us-
ing two validated high-pressure liquid chromatography with
tandem mass spectrometry (LC/MS/MS) methods, high range
and low range (SFBC Taylor, Princeton, NJ). Enzastaurin
(LY317615) and its two active metabolites (LY326020 and
LY485912) were also detected using a validated LC/MS/MS
method (Advion BioSciences, Inc., Ithaca, NY).
Pharmacokinetic (PK) parameters for enzastaurin, its
metabolites LY326020, LY485912, and pemetrexed were
analyzed using noncompartmental methods (WinNonlin En-
terprise Version 5.0.1; Pharsight Corporation, Mountain
View, CA). PK parameters calculated for pemetrexed were
area under the concentration versus time curve from time zero
extrapolated to infinity (AUC0–inf), maximum observed con-
centration (Cmax), apparent clearance, apparent volume of
distribution, and terminal half-life (t[1/2]). PK parameters
calculated were AUC0–24 for QD enzastaurin or AUC0–12 for
BID enzastaurin, LY326020, LY485912, total analytes (en-
zastaurin  LY326020  LY485912), Cmax, and the ob-
served time to reach peak drug concentration (tmax). PK
parameters between cycle 1 and cycle 2 were compared to
evaluate the effect of the loading dose to reach steady state in
a short time. AUC0–24 for QD enzastaurin or AUC0–12 for
BID enzastaurin, Cmax, tmax, and metabolic ratio (metabolite
AUC/parent AUC) were also calculated for LY326020 and
LY485912.
Assessment of Tumor Response
Tumor measurement by radiologic imaging was done at
baseline and every 42 days during treatment. Poststudy eval-
uation was conducted 30  7 days after the last administra-
tion of enzastaurin. Tumor response was evaluated using the
RECIST guideline.23
Statistical Analyses
All patients who received at least one enzastaurin dose
were evaluated for safety, and those who received both
enzastaurin and pemetrexed at least once were evaluated for
efficacy. All analyses were descriptive, with no formal sta-
tistical test performed on the data from this study.
RESULTS
Patient Characteristics
Twelve patients were enrolled into the study at two
cancer center hospitals in Japan from November 2007 to
March 2008. All the 12 patients received at least one study
treatment: six patients each were enrolled in the QD (cohort 1)
and BID (cohort 2) groups. A single patient (cohort 1)
discontinued the study before pemetrexed administration be-
cause of an adverse event. Baseline characteristics for the 12
patients are summarized in Table 1.
Dose Administration
In the study, a total of 91 cycles of therapy were
completed, with a median number of cycles per patient of 4
(range, 1–19). Five patients (two in QD and three in BID)
received more than 10 cycles of therapy (range, 13–19).
The reasons for discontinuation during the first four
cycles were disease progression (n  5) and adverse events
(n  2). Nine dosing delays of pemetrexed during the four
cycles occurred in six patients because of adverse events
(four in three patients), scheduling conflict (three in three
patients), and others (two in one patient).
Toxicities
All 12 patients were evaluated for toxicities during the
first four cycles. Table 2 lists all grade 3/4 drug-related
toxicities; all drug-related toxicities with at least a 20%
incidence in the overall population, regardless of grade, are
also shown. One patient (BID) experienced grade 4 hemato-
logical toxicities: neutropenia, anemia, and thrombocytope-
nia. Grade 3 hematological toxicities occurred in four pa-
tients. Grade 4 nonhematological toxicities were not
observed. All grade 3/4 toxicities were reversible and man-
ageable, except for toxicities whose recovery could not be
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confirmed because of disease progression. During the first
four cycles, two patients discontinued the study because of
drug-related toxicities: grade 3 QTc prolongation (QD) and
grade 1 increased serum creatinine (BID). Four dosing delays
of pemetrexed occurred in three patients (one in QD and two
in BID) because of adverse events: neutropenia, thrombocy-
topenia, anemia, increased alanine transaminase, hyponatre-
mia, and increased blood creatinine. Grade 3/4 hematological
toxicities were slightly increased in BID dosing compared
with QD dosing.
One DLT was reported: grade 3 QTc prolongation was
observed 1 day after the enzastaurin loading dose in the QD
cohort. This male patient with a history of coronary spastic
angina experienced asymptomatic QTc prolongation 60
milliseconds over baseline (baseline: 430 milliseconds, post
dose: 510 milliseconds). Enzastaurin was halted and his QTc
normalized (420 milliseconds) in 6 days without the need of
any medication. The patient was withdrawn from the study
because of the event. There were no treatment-related deaths.
Treatment Response
Other than the single patient who discontinued before
administration of pemetrexed because of DLT, all patients
were assessed for response. Based on the results at the end of
the study, two patients (one in QD and one in BID) (18%)
achieved partial response (PR) and five patients (two in QD
and three in BID) (45%) had stable disease (SD). Five
patients (45%) received more than 10 cycles of treatment
without disease progression.
Pharmacokinetics
PK parameters after 500 mg QD or 250 mg BID dosing
of enzastaurin are shown in Table 3. The Cmax for total
analyte was reached within about 2 hours after BID dosing
and about 5 hours after QD dosing. Total analytes in both
BID and QD dosing declined in a monophasic manner after
reaching maximum concentrations (Figure 2). Total analyte
exposure (enzastaurin and its metabolites AUC,ss) of enza-
staurin was approximately 21% and 3% lower, respectively,
for 500 mg QD and 250 mg BID when administered with
pemetrexed (cycle 2) compared with administration of enza-
staurin alone (stage 1 in cycle 1). Maximum concentrations
(Cmax,ss) of total analyte were 14% and 2% lower, respec-
tively, for 500 mg QD and 250 mg BID when administered
with pemetrexed (cycle 2) compared with administration of
enzastaurin alone (stage 1 in cycle 1) (Figure 2 and Table 3).
Compared with QD dosing, there was a higher mean expo-
sure for BID dosing. Total analyte concentrations reached
TABLE 1. Patient Characteristics
500 mg QD
(n  6)
250 mg BID
(n  6)
Total
(n  12)
Age, yr
Median 63.5 59.0 61.5
Range 49–74 49–71 49–74
Gender, n (%)
Male 5 3 8
Female 1 3 4
ECOG PS, n (%)
0 4 4 8
1 2 2 4
Histology, n (%)
Adenocarcinoma 5 3 8
Squamous cell carcinoma 1 2 3
Undifferentiated NSCLC 0 1 1
Disease stage, n (%)
IIIB 1 3 4
IV 4 3 7
Relapse after surgery 1 0 1
Prior therapy, n (%)
Chemotherapya
1 regimen 3 3 6
2 regimens 3 3 6
Surgery 1 0 1
Radiotherapy 3 4 7
a Cisplatin-gemcitabine, carboplatin-paclitaxel, cisplatin-S1, cisplatin-vinorelbine,
docetaxel, gefitinib, and others.
ECOG, eastern cooperative oncology group; NSCLC, non-small cell lung cancer.
TABLE 2. All Grade 3/4 Toxicities and Toxicities with at
Least 20% Incidence
Toxicity, n
500 mg QD
(n  6)
250 mg BID
(n  6)
Overall
(n  6)
Any
Grade
Grade
3/4
Any
Grade
Grade
3/4
Any
Grade
Grade
3/4
Nonhematological
toxicity
Chromaturia 5 0/0 6 0/0 11 0/0
Anorexia 5 0/0 5 0/0 10 0/0
Rash 5 0/0 5 0/0 10 0/0
Increased ALT 4 1/0 5 1/0 9 2/0
Increased AST 4 1/0 5 1/0 9 2/0
Fatigue 3 0/0 4 0/0 7 0/0
Nausea 4 0/0 3 0/0 7 0/0
Constipation 3 0/0 1 0/0 4 0/0
Discolored faeces 1 0/0 3 0/0 4 0/0
Hyponatremia 1 0/0 3 2/0 4 2/0
Increased LDH 1 0/0 3 0/0 4 0/0
Diarrhea 1 0/0 2 0/0 3 0/0
Fever 2 0/0 1 0/0 3 0/0
Hematuria 2 0/0 1 0/0 3 0/0
Hypoalbuminemia 1 0/0 2 0/0 3 0/0
Increased ALP 2 0/0 1 0/0 3 0/0
Arthralgia 2 1/0 0 0/0 2 1/0
QT prolongation 1 1/0 1 0/0 2 1/0
Hematological
toxicity
Anemia 5 0/0 5 0/1 10 0/1
Leukocytopenia 4 1/0 4 2/0 8 3/0
Lymphocytopenia 3 1/0 4 0/0 7 1/0
Neutropenia 3 1/0 3 2/1 6 3/1
Thrombocytopenia 2 0/0 2 1/1 4 1/1
Common Toxicity Criteria for Adverse Events version 3.0.
ALT, alanine transaminase; AST, aspartateaminotransferase; LDH, lactate dehy-
drogenase; ALP, alkaline phosphatase.
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steady-state by day 8 of cycle 1, with mean steady-state
concentrations (CV %) of 2850 nmol/L (53.5%) and 3420
nmol/L (39.5%) after QD and BID dosing, respectively (Fig-
ure 3). Total analyte exposure in cycle 1 was relatively higher
than that in cycle 2, suggesting that the loading dose regimen
of enzastaurin was instrumental in achieving a steady-state
level of total analytes on day 2.
PK parameters of pemetrexed for QD and BID dosing
are summarized in Table 4. Pemetrexed declined in a tripha-
sic manner with an elimination half-life of 3.22 hours, which
was consistent with previous observations of pemetrexed
single dosing.24 Interpatient variability in CL and Vss was
less than 40%, implying constant systemic exposure to pem-
etrexed. Pemetrexed pharmacokinetics were not altered by
enzastaurin dosing regimen, either QD or BID.
DISCUSSION
PKC overexpression and increased activity have been
detected in a variety of tumors including several hematolog-
ical malignancies, colon cancer, renal cell cancer, hepatocel-
lular cancer, prostate cancer, and NSCLC.25–30 Enzastaurin, a
potent PKC inhibitor has been shown to have antiangiogenic
and antitumor effects in NSCLC.13,14,20,31 The synergic anti-
tumor activity of enzastaurin and pemetrexed combination
was shown in NSCLC cell lines,18–20 and previous combina-
tion studies of enzastaurin with cytotoxic agents showed neither
increased toxicity nor PK drug-drug interactions.15,16,31,32 There-
fore, in this study, we decided to assess safety of the recom-
mended clinical doses of enzastaurin and pemetrexed (enza-
staurin 500 mg/d and pemetrexed 500 mg/m2).
The combination regimen was well tolerated for both
QD and BID dosing. The observed range of grade 3/4
toxicities in this study was consistent with those seen in the
monotherapy studies of enzastaurin and pemetrexed. All
grade 3/4 toxicities, including DLT, were reversible and
manageable. One patient with a history of ischemic heart
disease developed grade 3 QTc prolongation that was con-
sidered a DLT. However, this event was asymptomatic and
FIGURE 2. Plasma concentration of enzastaurin
total analytes. Arithmetic mean (SD) total analytes
(enzastaurin and its metabolites) plasma concen-
tration time profiles after enzastaurin administered
500 mg once daily (QD) or 250 mg twice daily
(BID) without concurrent pemetrexed (QD, open
circle; BID, open square) or with concurrent pem-
etrexed (QD, black circle; BID, black square).
TABLE 3. Pharmacokinetic Parameters of Enzastaurin Total Analytes
Parameter
Geometric Mean (CV%)
500 mg QD 250 mg BID
Cycle 1, Day 2 One Day After
Loading Dosea
Cycle 2, Day 1 (Steady State)
 Pemetrexed
Cycle 1, Day 2 One Day After
Loading Dosea
Cycle 2, Day 1 (Steady State)
 Pemetrexed
N 6 4 6 5
Cmax (nmol/L) 4870 (36.0) 4200 (50.1) 4420 (44.5) 4340 (31.3)
tmax
b (h) 4.99 (0.00–6.00) 5.09 (2.02–8.02) 1.97 (1.78–3.95) 2.23 (1.93–4.22)
AUC,ss (nmol/Lh) 86200 (36.1) 68500 (53.5) 42400 (49.3) 41100 (39.5)
Cav,ss (nmol/L) NC 2850 (53.5) NC 3420 (39.5)
a Non-steady-statevalues, AUC,ss  AUC(0–24 h) (QD) or AUC(0–12 h) (BID).
b Values are in median (range).
BID, twice daily; QD, once daily; N, numberof subjects used in the pharmacokinetic analysis; Cmax, maximum plasma concentration; tmax, time to reach maximumconcentration;
AUC,ss, area under the concentration versus timecurve during one dosing interval at steady state (QD  24 h and BID  12 h); Cav,ss, average drug concentration under steady-state
conditions during multipledosing; CV, coefficient of variation; NC, not calculated.
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transient. In the enzastaurin preclinical toxicology study in
dogs, prolonged QT and QTc values were observed after 5
weeks of dosing at a high daily dose of enzastaurin. In the
enzastaurin phase I study in recurrent glioma patients, one
grade 3 QTc prolongation was also reported.33
The PK results of this study indicated no significant PK
interaction between enzastaurin and pemetrexed, which was
consistent with a previously published phase I study report.32
One possible reason for the absence of any effect on phar-
macokinetics was the different pathways used for elimina-
tion. Pemetrexed is renally eliminated, whereas a phase I
study using [14C] enzastaurin indicated that enzastaurin un-
dergoes extensive hepatic metabolism with minimal renal
elimination (Eli Lilly and Company, Internal Clinical Study
Report, October 2006). Based on these results, it is not likely
that enzastaurin and its metabolites inhibit the renal elimina-
tion of pemetrexed. In fact, a previous combination study of
enzastaurin with pemetrexed reported by Hanauske et al.17
showed that pemetrexed pharmacokinetics (systemic clear-
ance and half-life) did not seem to be altered by enzastaurin.
In addition, it is not likely that pemetrexed inhibits the
metabolism of enzastaurin by CYP3A4 because results from
in vitro studies with human liver microsomes predicted that
pemetrexed would not cause clinically significant inhibition
of metabolic clearance of drugs metabolized by CYP3A,
CYP2D6, CYP2C9, and CYP1A2.34 In this study, the com-
paratively high concentrations observed in cycle 1 resulted
from the large loading dose on day 1 of cycle 1. In addition,
we confirmed two more findings that were reported by
Hanauske et al.17 First, the maximum concentrations (Cmax,ss)
of total analyte in both QD and BID regimens were slightly
decreased in the presence of pemetrexed (14% QD and 2%
BID in this study; 17% QD and 8% BID in the Hanauske
phase Ib study). Second, the average steady-state plasma
concentration (Cav,ss) of enzastaurin total analyte was slightly
higher in the BID versus QD regimen (20% higher in this
study and 11% higher in the Hanauske phase Ib study).
In light of the fact that two patients achieved PR, five
patients achieved SD, and five patients remained on therapy
for more than 9 months (13 cycles), the results from this
study suggest that the combination of enzastaurin and pem-
etrexed might be beneficial in previously treated patients with
advanced NSCLC. The histology of both the patients who
achieved PR was nonsquamous cell carcinoma. One of three
patients with squamous cell carcinoma remained on therapy
for 14 cycles with SD, whereas PD was observed during
cycle 1 for the other two patients. Further research is war-
ranted to determine whether enzastaurin might improve the
effect of pemetrexed that works preferentially in nonsqua-
mous cell carcinoma.
FIGURE 3. Pharmacokinetic result of enzastaurin: trough concentration of total analytes. Arithmetic mean (solid circles), SD,
and individual trough concentrations (lines) of enzastaurin total analytes (enzastaurin and its metabolites) after enzastaurin
administered 500 mg once daily (A) or 250 mg twice daily (B) without or with concurrent pemetrexed.
TABLE 4. Pemetrexed Pharmacokinetic Parameters After
Enzastaurin Dose
Parameter
Geometric Mean (CV%)
Enzastaurin
(Cycle 2)
500 mg QD
Enzastaurin
(Cycle 2)
250 mg BID
Enzastaurin
(Cycle 2)
250 mg BID
and 500 mg QD
N 4 5 9
Cmax (g/mL) 143 (20.4) 127 (10.6) 134 (15.8)
tmax
a (h) 0.15 (0.15–0.18) 0.15 (0.15–0.17) 0.15 (0.15–0.18)
AUC(0–)
(gh/mL)
265 (38.1) 236 (36.3) 248 (35.2)
CL (L/h/m2) 1.88 (38.3) 2.12 (36.3) 2.01 (35.2)
Vss (L/m
2) 5.70 (17.3) 6.12 (9.60) 5.93 (13.1)
t1/2
b (h) 3.13 (2.67–3.60) 3.29 (2.42–4.85) 3.22 (2.42–4.85)
a Values are in median (range).
b Values are in geometric mean (range).
AUC(0–), area under the plasma concentration time curve; CL, systemic clear-
ance; Cmax, maximum plasma concentration; CV, coefficient of variation; N, number
ofpatients; t1/2, elimination half-life; tmax, time of maximal plasma concentration; Vss,
volume ofdistribution at steady state.
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In conclusion, combination therapy for enzastaurin ad-
ministered QD or BID with pemetrexed was well tolerated
and clinically active in patients with previously treated ad-
vanced NSCLC. Both dosing regimens of enzastaurin did not
affect pemetrexed pharmacokinetics, and enzastaurin expo-
sures remained above the targeted plasma concentration in
the presence of pemetrexed. Enzastaurin exposures were
higher with the BID regimen, with slightly more grade 3/4
hematological toxicities. These were manageable and BID
dosing did not indicate any major tolerability issues.
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